SOUTH SAN FRANCISCO, Calif. — August 6, 2025 — Leads & Copy — Allogene Therapeutics, Inc. (Nasdaq: ALLO) will report its second quarter 2025 financial results and provide a business update on August 13, 2025, after market close. A live audio webcast and conference call will follow at 2:00 p.m. PT/5:00 p.m. ET.
The listen-only webcast will be available on the company’s website. A replay will be available for about 30 days.
Those wanting to ask a question on the conference call can register via a link to receive a personal PIN to access the call.
Allogene Therapeutics is a clinical-stage biotechnology company that is pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease.
Christine Cassiano, EVP, Chief Corporate Affairs & Brand Strategy Officer, can be reached at Christine.Cassiano@allogene.com.
Source: Allogene Therapeutics, Inc.
